Topics

Histology independent cancer drugs: the drug makers’ responsibility

10:45 EST 3 Feb 2020 | British Medical Journal

Cooper and colleagues raise important challenges for health technology assessment (HTA) organisations in evaluating the benefits, risks, and cost effectiveness of drugs that target a genetic mutation...

Original Article: Histology independent cancer drugs: the drug makers’ responsibility

NEXT ARTICLE

More From BioPortfolio on "Histology independent cancer drugs: the drug makers’ responsibility"

Quick Search